Agenus

OverviewSuggest Edit

Agenus is a clinical-stage immuno-oncology company which focuses on the discovery and development of therapies that engage the body's immune system for patients suffering with cancer. The Company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies, SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies, and phage display technologies. It is also developing checkpoint modulating antibody candidates. In addition, the Company develops cancer and tumor vaccine programs and a saponin-based vaccine adjuvant for the treatment of malaria and shingles.

TypePublic
Founded1994
HQLexington, USMap
Websiteagenusbio.com
Employee Ratings3.6More
View Jobs (6)

Recent NewsAll News

Latest Updates

Employees (est.) (Feb 2020)328(+12%)
Job Openings6
Revenue (FY, 2019)$150 M(+308%)
Share Price (May 2020)$3.7 (+30%)

Key People/Management at Agenus

Garo H. Armen

Garo H. Armen

Chairman and CEO
Garo Armen

Garo Armen

Chairman and CEO
Jennifer Buell

Jennifer Buell

President and Chief Operating Officer
Anna Wijatyk

Anna Wijatyk

Vice President of Clinical Development
Julie Desander

Julie Desander

Vice President, Business Development and Alliance Management
Sunil Gupta

Sunil Gupta

Vice President of Regulatory & Pharmacovigilance
Show more

Agenus Office Locations

Agenus has offices in Lexington, Berkeley, New York and Cambridge
Lexington, US (HQ)
3 Forbes Rd
Berkeley, US
793 Heinz Ave
New York, US
149 5th Ave #500
Cambridge, GB
315 Science Park Milton Road
Show all (4)

Agenus Financials and Metrics

Agenus Revenue

Agenus's revenue was reported to be $150.05 m in FY, 2019
USD

Revenue (Q1, 2020)

15.1m

Net income (Q1, 2020)

(45.3m)

EBIT (Q1, 2020)

(27.5m)

Market capitalization (29-May-2020)

633.3m

Closing stock price (29-May-2020)

3.7

Cash (31-Mar-2020)

92.3m

EV

570.4m
Agenus's current market capitalization is $633.3 m.
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

16.0m3.0m7.0m24.8m22.6m42.9m36.8m150.0m

Revenue growth, %

129%256%(9%)

Cost of goods sold

672.0k536.1k

Gross profit

15.3m2.5m7.0m
Quarterly
USDQ2, 2011Q3, 2011Q4, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

786.4k653.7k2.8m13.4m626.8k868.8k1.1m807.4k736.0k720.9k3.1m1.6m4.0m6.4m6.8m6.0m6.6m4.4m27.0m4.2m3.4m1.6m15.9m12.8m79.9m15.7m19.9m15.1m

Cost of goods sold

23.7k128.5k217.2k272.8k176.7k80.1k

Gross profit

786.4k653.7k2.8m13.4m498.3k651.6k836.5k630.7k655.9k720.9k3.1m1.6m

Gross profit Margin, %

100%100%100%100%80%75%75%78%89%100%100%100%
show all
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

21.5m27.4m25.7m136.7m71.4m60.2m53.1m61.8m

Accounts Receivable

552.3k1.2k9.8m11.4m1.1m938.1k16.3m

Prepaid Expenses

545.9k658.4k1.2m2.0m11.1m19.3m7.4m

Inventories

16.0k95.7k88.2k88.2k79.5k55.5k
Quarterly
USDQ2, 2011Q3, 2011Q4, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

12.0m14.7m10.7m24.6m25.5m24.8m17.2m13.4m30.2m73.5m48.3m38.4m79.3m124.7m184.1m78.3m73.4m75.4m113.9m81.8m65.1m52.3m43.2m46.2m158.3m121.7m93.3m92.3m

Accounts Receivable

188.058.7k92.3k369.1k163.7k202.5k1.1k2.5m4.1m7.3m10.2m9.4m10.3m6.8m3.9m2.2m1.1m10.9m6.1m796.0k2.2m2.3m2.6m

Prepaid Expenses

830.7k771.6k536.3k804.5k691.5k631.8k887.6k738.8k655.2k1.3m1.1m1.4m2.5m1.8m2.0m2.8m2.8m3.0m6.6m8.9m10.8m11.1m12.9m14.5m18.1m13.6m10.4m6.9m

Inventories

26.4k26.4k20.1k18.6k18.6k16.0k16.0k4.0k3.3k95.7k95.7k88.2k88.2k88.2k88.2k88.2k88.2k87.5k87.0k80.2k62.2k55.5k55.5k55.0k55.0k55.0k
show all
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(11.3m)(30.1m)(42.5m)(87.9m)(127.0m)(120.7m)(162.0m)(111.6m)

Depreciation and Amortization

1.6m586.3k1.6m2.0m4.9m6.0m6.3m6.7m

Inventories

4.1k16.0k(95.7k)7.5k8.7k24.0k55.0k

Accounts Payable

(181.8k)189.6k(45.9k)2.7m419.7k1.6m5.4m(234.0k)
Quarterly
USDQ2, 2011Q3, 2011Q4, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Net Income

(11.7m)(17.3m)(23.3m)6.8m(155.4k)(5.9m)(5.8m)(17.0m)(24.3m)(357.5k)(8.4m)(16.5m)(18.7m)(59.2m)(72.3m)(31.8m)(60.1m)(100.9m)(17.1m)(48.8m)(85.7m)(54.3m)(79.5m)(113.2m)17.4m(34.4m)(80.7m)(45.3m)

Depreciation and Amortization

1.1m1.7m2.3m549.8k1.1m1.5m147.0k312.0k448.2k266.5k589.4k1.0m445.5k885.5k1.4m1.2m2.5m3.7m1.5m3.1m4.6m1.6m3.1m4.7m1.6m3.3m5.0m1.7m

Inventories

6.4k1.5k1.5k4.1k(12.0k)(12.7k)(95.7k)(95.7k)7.5k7.5k7.5k8.0k17.3k24.0k24.0k

Accounts Payable

(358.5k)(215.2k)105.7k(467.5k)(175.9k)(340.1k)(149.7k)(242.1k)(269.4k)184.0k(562.1k)35.2k2.3m797.8k1.3m(2.3m)474.5k(1.3m)(1.1m)(1.2m)1.0m(2.8m)1.7m2.9m(860.0k)5.6m3.1m1.2m
show all
USDY, 2020

EV/EBIT

-20.8 x

EV/CFO

-16.5 x

Revenue/Employee

46.1k

Financial Leverage

-0.9 x
Show all financial metrics

Agenus Online and Social Media Presence

Agenus's Trends

Embed Graph

Agenus News and Updates

February 20, 2020

Agenus Announces Positive Interim Data from Balstilimab and Zalifrelimab Clinical Trials in Second-Line Cervical Cancer

LEXINGTON, Mass., Feb. 20, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers, today announced new clinical data from pre-planned interim analyses of balstilimab (anti-PD-1) and...
December 19, 2019

Agenus Commences Combination Trial of its Next-Gen CTLA-4 with its PD-1 Antibody

LEXINGTON, Mass., Dec. 19, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1 and cancer vaccines, today announced the first patient dosed with AGEN1181, an anti-CTLA-4 antibody, in...
August 06, 2019

Agenus to Report Second Quarter 2019 Financial Results on August 8, 2019 and Host Conference Call and Webcast

LEXINGTON, Mass., Aug. 6, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, will release its second quarter 2019 financial results before the market opens on Thursday, August 8, 2019. Agenus...
June 13, 2019

Agenus to Host Annual Meeting of Stockholders

LEXINGTON, Mass., June 13, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, invites investors and the general public to attend its annual meeting of...
May 09, 2019

Agenus Reports First Quarter 2019 Financial Results and Provides Corporate Update

LEXINGTON, Mass., May 9, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, provided corporate updates and reported financial results for the first quarter of 2019....
May 03, 2019

Agenus to Report First Quarter 2019 Financial Results on May 9, 2019 and Host Conference Call and Webcast

LEXINGTON, Mass., May 3, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, will release its first quarter 2019 financial results before the market opens on...
Show more

Agenus Blogs

March 12, 2020

Agenus Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

- AGEN1181 +/- balstilimab (anti-PD-1) reveals a complete response and new partial responses in phase 1 clinical trial
March 10, 2020

First QS-21 Royalty Payment Due to Agenus is Triggered

$15.1M Milestone from HealthCare Royalty Partners
March 03, 2020

Agenus to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020 with Conference Call and Webcast

February 06, 2020

Agenus Announces Investor Day on February 20, 2020

January 09, 2020

Agenus Announces the Appointment of Dr. Jennifer Buell to the position of President and COO

January 08, 2020

Agenus Commences Phase 1 trial with AGEN1223

- AGEN1223 is a novel bi-specific designed to selectively deplete regulatory T cells in the tumor microenvironment
Show more

 Agenus Frequently Asked Questions

  • When was Agenus founded?

    Agenus was founded in 1994.

  • Who are Agenus key executives?

    Agenus's key executives are Garo H. Armen, Garo Armen and Jennifer Buell.

  • How many employees does Agenus have?

    Agenus has 328 employees.

  • What is Agenus revenue?

    Latest Agenus annual revenue is $150 m.

  • What is Agenus revenue per employee?

    Latest Agenus revenue per employee is $457.5 k.

  • Who are Agenus competitors?

    Competitors of Agenus include LogicBio Therapeutics, ABL Bio and Shanghai Henlius Biotech.

  • Where is Agenus headquarters?

    Agenus headquarters is located at 3 Forbes Rd, Lexington.

  • Where are Agenus offices?

    Agenus has offices in Lexington, Berkeley, New York and Cambridge.

  • How many offices does Agenus have?

    Agenus has 4 offices.